Extended Data Table 2 Subgroup analysis: efficacy analysis of patients by ER expression subgroups

From: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

  1. CI, confidence interval; ER, estrogen receptor; HR, hormone receptor; OS, overall survival; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician’s choice of chemotherapy.
  2. aHR− cohort data included in this table are equivalent to ER-negative subgroup data.
Back to article page